Impact of Number of Pregnancies on Allosensitization and Heart Transplant Outcomes

Abstract

after a significantly longer median wait (P< 0.001) [Table 1]. The adjusted probability of survival at 2 years was 49% in group I versus 67% in group II (P< 0.001). Among patients who underwent HT, the adjusted probability of survival in groupI versus group II was 84% versus 73%, respectively (ns), though, in the subgroups treated with inotropes, was 84% in groupI versus 66 % in group II (P= 0.01). The mean 2-year cost was € 390,833±178,998 per patient in group I versus € 65,154±30,258 in groupII (P= 0.002). Conclusion: In ESHF with inotropes, VAD were clinically effective, did not lower survival after HT, though were an expensive strategy.